International Journal of Medicine and Pharmaceutical Research
Journal Home Page: www.pharmaresearchlibrary.com/ijmpr
CODEN (USA): IJCPNH | ISSN: 2321-2624 | Publisher: Pharma Research Library
DOI: https://doi.org/10.30904/j.ijmpr.2024.4631
Int. J. Med. Pharm. Res., 2024, 12(1): 05-11

# Review Article on Community-Acquired Pneumonia

Meejuri Pallavi[1], Raju Divya Sri[1], Yekollu Niharika Reddy[1], Potluri Vasanthi[1], SK. Meharunnisa[2], Dr. Y. Prapurna Chandra[3]
[1]Vth year PharmD student, Ratnam Institute of Pharmacy, Pidathapour, Nellore
[2]Assistant Professor, Department of Pharmacy Practice, Ratnam Institute of Pharmacy, Pidathapour, Nellore
[3]Principal, Department of Phamacology, Ratnam Institute of Phamacy, Pidathapour, Nellore

**A B S T R A C T**
Community- acquired pneumonia (CAP) is a constantly being acute illness that necessitates sanitarium admission and contributes significantly to patient morbidity and healthcare cost. It remains a common cause of morbidity and mortality worldwide, affecting roughly 5.6 million cases annually in the USA. The primary infections responsible with CAP are Mycoplasma pneumoniae, Chlamydophila pneumoniae, influenza A, Streptococcus pneumoniae, and age are the main threat factors, along with smoking and comorbidities. This review covers the pathogenesis, threat assessment, biomarkers, epidemiology, and treatment of community- acquired pneumonia (CAP). A number of comorbidities, similar as asthma, heart failure, and chronic obstructive pulmonary complaint (COPD), are threat factors for community- acquired pneumonia. The most common signs and symptoms are dyspnoea, cough, fever, and new focal signs. Results may be enhanced by the routine use of biomarkers to enhance threat assessment and customize treatment for specific cases. The opinion of CAP is grounded on clinical signs and the presence of a pulmonary insinuate visible on the radiograph. The British Thoracic Society(BTS) established the original inflexibility score Check (confusion, uraemia, respiratory rate, low blood pressure) to identify cases with CAP who may be campaigners for inpatients. Inpatient treatment Biomarkers, such as procalcitonin (PCT), can be used to guide management throughout hospital stay. Antibiotic regimen will vary depending on whether inpatient and outpatient management is needed.

**Keywords**: Community-acquired pneumonia, comorbidities, biomarkers, procalcitonin, check, antibiotic

**A R T I C L E I N F O**

***Corresponding Author**
Meejuri Pallavi
Vth year PharmD student,
Ratnam Institute of Pharmacy,
Pidathapour, Nellore

**Article History:**
Received : 10 Sept 2023
Revised : 18 Oct 2023
Accepted : 29 Nov 2023
Published : 07 Jan 2024



***Citation:*** *Meejuri Pallavi, et al. Review Article on Community-Acquired Pneumonia. Int. J. Med. Pharm. Res., 2024, 12(1): 05-11.*

**Contents**



## 1. Introduction

Community acquired pneumonia (CAP) is one of the most common serious infective diseases leading to hospitalization on a global scale. It can affect individuals of any age and beget significant strain on the healthcare system due to its economical burden; but more importantly, it carries significant morbidity and mortality. Utmost of the mortality occurs in cases that bear hospitalization. The understanding of the multiple factors about CAP, similar as the prevalence, epidemiology can help us guide preventative measures and treatments. Addition to the preliminarily mentioned benefits, the explanation for this literature review is to punctuate the advantages of applicable threat- position in directing care, as well as some of the remedial benefits of employing procalcitonin as a pneumonia biomarker. It has been demonstrated that procalcitonin is a promising inflammatory biomarker that

can track how well a case is responding to remedy. According to the exploration, procalcitonin is better at directing suitable drug than other biomarkers like CRP. Procalcitonin situations will steadily rise in cases with CAP throughout a follow- up, which emphasizes the significance of follow- up measures. Still, procalcitonin can also increase in non-infectious conditions. We can calculate the case's probability of death using applicable severity scales like CURB and PSI. As a result, this severity scale can help in determining which cases need the adequate care and can also help identify individualities who may be more likely to witness CAP- related morbidity and death. Because of our extensive disquisition into the pathophysiologic mechanisms of community- acquired pneumonia (CAP) in humans, a variety of potent antimicrobial medicines have been created to prevent infection. When it comes to treating CAP, empirical treatment is favoured, but there are hazards involved, including adherence problems, antibiotic resistance, and antibiotic abuse. Medical professionals need to be alive that in 25 of cases, CAP has a viral origin, which could explain unusual symptoms or a poor response to specifics. Rapid opinion and identification of a viral- CAP can significantly enhance results and lower mortality, particularly during influenza season.

**2. Epidemiology**

Incidence — CAP is one of the most common and morbid conditions encountered in clinical practice. In the United States, CAP accounts for over4.5 million inpatient and intensive care unit room visits annually, corresponding to roughly 0.4 percent of all rendezvous. CAP is the alternate most common cause of hospitalization and the most common contagious cause of death. Roughly 650 people are rehabilitated with CAP every time per 100,000 population in the United States, corresponding to 1.5 million unique CAP hospitalizations each time. Nearly 9 percent of cases rehabilitated with CAP will be re-hospitalized due to a new occasion of CAP during the same time.

**Causes:**

The most commonly found pathogens in individuals with community-acquired pneumonia (CAP) are respiratory viruses and Streptococcus pneumoniae (pneumococcus). However, despite thorough microbiologic investigation, no pathogen is found in a significant number of cases (up to 62 percent in certain studies conducted in hospital settings).

**Risk factors:**

- Older age: Between the ages of 7 and 8, the risk of CAP increases. In the US, there are roughly 2000 hospital admissions for CAP for every 100,000 persons over the age of 65. This number suggests that 2 percent of older adults will be hospitalized for CAP each year, which is around three times more than the overall population.
- Chronic comorbidities: Chronic obstructive pulmonary disease (COPD), which has an annual incidence of 5832 per 100,000 in the US, is the comorbidity that puts patients at highest risk for CAP hospitalization. further chronic lung diseases (such as asthma and bronchiectasis), chronic heart disease (especially congestive heart failure), stroke, diabetes mellitus, malnourishment, and immunocompromising disorders are further comorbidities linked to an increased risk of community-acquired pneumonia (CAP).
- Viral respiratory tract infection: Viral respiratory tract infections are the risk factors for both subsequent bacterial pneumonia and initial viral pneumonia. When there is an influenza virus infection, this is most evident.
- Disabled airway protection: Conditions that increase threat of macro aspiration of stomach contents and micro aspiration of upper airway secretions predispose to CAP.
- Alcohol abuse and smoking: The three main modifiable behavioural risk factors for CAP are opiate use, alcohol abuse (e.g., >80 g/day), and smoking.
- Additional elements of lifestyle: A higher chance of developing CAP has also been linked to living in densely populated areas (such as jails or homeless shelters), being in low-income neighbourhoods, and being exposed to environmental contaminants (such as paints, solvents, or gasoline).

**Additional elements of lifestyle:** A higher chance of developing CAP has also been linked to living in densely populated areas (such as jails or homeless shelters), being in low-income neighbourhoods, and being exposed to environmental contaminants (such as paints, solvents, or gasoline). The risk associated with a combination of risk factors is additive, such as smoking, congestive heart failure, and COPD. These risk factors as well as additional circumstances that predispose the development.

**3. Pathophysiology**

When a pathogen cannot be removed by the immune system from the lower airway and alveoli, pneumonia, an alveolar infection, results. The release of cytokines and local inflammatory mediators by immune cells damages the lung parenchyma. This causes systemic inflammation, which then gives rise to secondary symptoms like chills, fever, and exhaustion. Pus forms in the parenchyma as a result of WBC accumulation and fluid congestion, which lowers alveolar compliance. These modifications exacerbate tachypnoea and hypoxemia while making breathing harder for the patient. The likelihood of developing CAP can be raised by clinical comorbidities that impair cough reflex and mucociliaryclearance. Patients are also more vulnerable as a result of social practices like smoking. It's also important to be aware of medical issues including neuromuscular and oesophageal diseases that raise the risk of aspiration.

**Risk analysis:**

Based on a 30-day mortality risk, pneumonia evaluation systems like PSI and CURB were created to provide the right kind of care. These instruments are sometimes used to determine which patients need to be admitted to the intensive care unit (ICU) and to direct the proper empirical antibiotic treatment. Pneumonia Severity Index PSI,

sometimes referred to as the Fine score, divides CAP patients into five groups according to how likely they are to pass away in the next 30 days. 3. Twenty clinical, laboratory, and radiographic characteristics from data validated on over 40,000 inpatients make up the score.

**CURB:**

The original CURB was created by the British Thoracic Society (BTS) to determine which CAP patients would benefit more from outpatient as opposed to inpatient care. CURB and PSI vary in that the former does not target underlying disease directly.

**Among the requirements for CURB are:** These criteria are credible, with the exception of elderly patients and those with underlying renal impairment. The modified six-point CURB-65 score was developed using a multivariate analysis of 1,068 patients. This score comprises the same criteria as previously mentioned, plus the additional criterion of Age > 65 years. ICU care is indicated by a score of at least 3. Because it assesses the severity of CAP versus the risk of mortality directly, the CURB score methodology is typically preferred over the PSI method.

**Inflammatory Biomarkers in CAP:**

Description: A biomarker is" a characteristic that's objectively measured as an index of pathogenic processes, normal natural processes, or pharmacologic responses to a remedial intervention". In order to establish whether antibiotic regimen is necessary, an ideal individual biomarker for CAP should only be raised in cases of bacterial illness and not in cases of viral or fungal infection. Common inflammatory biomarkers used in the opinion of **CAP are:**

White blood cell count, CRP, PCT, sTREM- 1, pro ADM, Presepsin.CAP, community-acquired pneumonia; CRP, C-reactive protein; PCT, procalcitonin; sTREM-1, soluble triggering receptor expressed on myeloid cells-1; pro ADM, pro-adrenomedullin.

**Procalcitonin:**

When patients are admitted for CAP, procalcitonin testing can assist distinguish between bacterial and viral infections, allowing for the timely de-escalation of empirical therapy and avoiding the need for needless antibiotic administration. This is more successful than using clinical judgment alone. Although procalcitonin levels can be elevated by any infectious pneumonia, procalcitonin levels are generally higher in response to typical bacteria than in response to atypical bacteria or viruses. Procalcitonin release is enhanced by cytokines, which are linked to bacterial infections, and inhibited by interferons, which are linked to viral infections. But this biomarker is not ideal; in up to 23% of common bacterial illnesses, it will not be raised. Procalcitonin can therefore be used in concert with clinical judgment to de-escalate therapy rather than taking the place of clinical judgment when deciding whether to start antimicrobial therapy for patients with suspected CAP. Antibiotics can be stopped in patients whose clinical histories point to other causes of respiratory distress or improvement with concurrently administered therapy such diuresis. A negative procalcitonin result can help with this decision. Conversely, in individuals whose influenza is confirmed by polymerase chain reaction, an increased procalcitonin level may indicate that medications should be continued to treat bacterial super infection. While biomarkers are helpful in distinguishing CAP from other non-infectious respiratory disorders, their usage should be complementary rather than solely based on them.

**Management of community-acquired pneumonia:**

Antibiotic regimen is started primarily on empirical data. Depending on how adequate the care is demanded, several recommendations are made for treating admitted patients. After initiating intravenous (IV) treatment until their condition improves, the maturity of in-patient cases move on to oral administration. In cases admitted to the general ward who do not appear to have Pseudomonas or any other multidrug resistant pathogens, the following tradition medicines are advised. Several association's agreement guidelines suggest using doxycycline, macrolides, or fluoroquinolones as an empirical treatment. After their symptoms subside, they come alert, and they can handle oral drugs, in-patient cases should transition from parenteral antibiotics to oral antibiotics. Clinical pathways are pivotal for enhancing patient care and maximizing cost-effectiveness while they're in the health care setup.

## 4. Conclusion

CAP is the alternate most frequent reason for hospitalizations and the primary cause of mortality associated to contagious conditions in the US. All age groups and health conditions can be affected, still geriatric people regard for the most of hospitalizations. Sputum is generally the most prominent symptom of conventional pneumonia, though clinical symptoms might vary depending on the cause of CAP. The correct discovery of legion fever complaint depends on laboratory- grounded identification tests in addition to the clinical and radiological discovery of pneumonia, as recent exploration has demonstrated that the complaint can present with radiographic and tomographic symptoms that are analogous to those of typical CAP. The control of CAP tends to be empirical antibiotic treatment, which can present with vulnerability. Still, with proper severity scale indexes, similar as CURB and PSI, we can often guide antibiotic treatment. We hope that through this literature review, we've spread perception about the frequency of CAP and the value of risk analysis, using procalcitonin as a biomarker and the numerous considerations to be apprehensive of in terms of antibiotic regimen administration.

| Typical bacteria | **Atypical bacteria** | **Respiratory viruses** |
|---|---|---|
| S.Pneumoniae | Legionella spp | Infuenza A and B viruses |
| Haemophilus influenzae | Mycoplasma pneumoniae | Rhinoviruses |
| Moraxella catarrhalis | Chlamydia pneumoniae | Parainfluenza viruses |

| | | |
|---|---|---|
| Staphylococcus aureus | Chlamydia psittaci | Adenoviruses |
| Group A streptococci | Coxiella burnetil | Human bocaviruses |




| | | | |
|---|---|---|---|
| ANTIBIOTICS | Outpatient | Healthy | Amoxicillin 1 g TID<br>Or<br>Doxycycline 100 mg BID<br>Or<br>Azithromycin 500 mg 1st day then 250 mg QD ONLY if resistance <25% |
| | | Comorbidities (alcoholism, malignancy, chronic liver/renal/lung disease, diabetes, asplenia | Amoxicillin/clauvulanate 875 mg/125mg BID or cephalosporin AND Macrolide (azithromycin) or Doxycycline 100 mg BID<br>OR<br>Respiratory fluoroquinolone Monotherapy (levofloxacin / moxifloxacin / gemifloxacin) |
| | Inpatient | Severe or non-severe CAP but no risk factors for MRSA / pseudomonas (empirically treated, history of prior MRSA/ pseudomonas infection, or hospitalized w/IV antibiotics in past 90 days). | Beta-lactam + Macrolide (e.g. ceftriaxone + azithromycin)<br>OR<br>Respiratory fluoroquinolone Monotherapy (levofloxacin / moxifloxacin / gemifloxacin)<br>OR<br>Beta-lactam + Doxycycline |
| | | Inpatient with locally validated risk factors for MRSA or pseudomonas | MRSA - vancomycin<br>Pseudomonas - piperacillin-tazobactam or cefipime |
| | | Suspected aspiration | Do not routine add anaerobic coverage unless lung abscess or empyema suspected |
| Steroids | Inpatient | Not routinely recommended in non-severe CAP (strong recommendation, high quality evidence) or severe CAP (conditional recommendation, moderate quality evidence) | |

## 5. Bibliography

[1] Tajudeen BA, Kennedy DW. Thirty years of endoscopic sinus surgery: What have we learned? World J Otorhinolaryngol Head Neck Surg. 2017 Jan 21;3(2):115-121.

[2] Kane, K. (2020). The early history and development of functional endoscopic sinus surgery. The Journal of Laryngology & Otology, 134(1), 8-13.

[3] Al-Mujaini A, Wali U, Alkhabori M. Functional endoscopic sinus surgery: indications and complications in the ophthalmic field. Oman Med J. 2009 Apr;24(2):70-80.

[4] Vijay R. Ramakrishnan; Todd T. Kingdom; Jayakar V. Nayak; Peter H. Hwang; Richard R. Orlandi (2012). *Nationwide incidence of major complications in endoscopic sinus surgery. 2(1), 34–39.*

[5] Daniel G. Becker, MD, David W. Kennedy, MD, Indications for Endoscopic Sinus Surgery in Patients Seeking Aesthetic Rhinoplasty, *Aesthetic Surgery Journal*, 18, Issue 2, March 1998: 129–130.

[6] James A. Stankiewicz; DevyaniLal; Matthew Connor; Kevin Welch (2011). *Complications in endoscopic sinus surgery for chronic*

*rhinosinusitis: A 25-Year Experience., 121(12), 2684–2701.*

[7] Al-Madani, Mousa Victor; Khatatbeh, Ahmed Essa; Rawashdeh, Rania Zaid; Al-Khtoum, NemerFalah; Shawagfeh, Nabil Radwan (2013). *The prevalence of orbital complications among children and adults with acute rhinosinusitis. Brazilian Journal of Otorhinolaryngology, 79(6), 716–719.*

[8] Wormald PJ, van Renen G, Perks J, Jones JA, Langton-Hewer CD. The Effect of the Total Intravenous Anesthesia Compared with Inhalational Anesthesia on the Surgical Field during Endoscopic Sinus Surgery. *American Journal of Rhinology*. 2005, 19(5): 514-520.

[9] Ozkose, M., Baykan, H. &Coşkuner, İ. The Effect of Patient Positioning on Amount of Intraoperative Bleeding in Rhinoplasty: A Randomized Controlled Trial. *Aesth Plast Surg*, 2016, 40, 453–457.

[10] Leunig A. Vermeidung von und UmgangmitBlutungenwährendendoskopischerNasennebenhöhlenchirurgie [Avoiding and dealing with bleeding during endoscopic sinus surgery]. Laryngorhinootologie. 2006 Apr;85(4):249-52.

[11] Baradaranfar MH, Khadem J, TaghipoorZahir S, Kouhi A, Dadgarnia MH, Baradarnfar A. Prevention of adhesion after endoscopic sinus surgery: role of mitomycin C. Acta Med Iran. 2011;49(3):131-5. PMID: 21681698.

[12] Khanna, A., Sama, A. Managing Complications and Revisions in Sinus Surgery. *Curr Otorhinolaryngol Rep*, 2019, **7**, 79–86.

[13] Thompson CF, Wang MB, Kim BJ, Bergsneider M, Suh JD. Incidence and management of epistaxis after endoscopic skull base surgery. ORL J Otorhinolaryngol Relat, 2012; 74(6): 315-9.

[14] TunkelDE, Anne S, Payne SC, et al. Clinical Practice Guideline: Nosebleed (Epistaxis). Otolaryngology–Head and Neck Surgery. 2020;162(1_suppl): S1-S38.

[15] Anand VK, Tabaee A, Kacker A, Newman JG, Huang C. The Role of Mitomycin C in Preventing Synechia and Stenosis after Endoscopic Sinus Surgery. American Journal of Rhinology. 2004;18(5):311-314.

[16] Seredyka-Burduk M, Burduk PK, Wierzchowska M, Kaluzny B, Malukiewicz G. Ophthalmic complications of endoscopic sinus surgery. Braz J Otorhinolaryngol. 2017 May-Jun;83(3): 318-323.

[17] Cumberworth VL, Sudderick RM, Mackay IS. Major complications of functional endoscopic sinus surgery. Clin Otolaryngology Allied Sci. 1994 Jun;19(3): 248-53.

[18] Rodriguez MJ, Dave SP, Astor FC. Periorbital emphysema as a complication of functional endoscopic sinus surgery. Ear Nose Throat J. 2009, 88(4): 888-9.

[19] Rodriguez MJ, Dave SP, Astor FC, Sandeep P, Frank C. Periorbital Emphysema as a Complication of Functional Endoscopic Sinus Surgery. Ear, Nose & Throat Journal. 2009, 88(4): 888-889.

[20] Muzumdar D, Nadkarni T, Goel A. Spontaneous cerebrospinal fluid rhinorrhea as a presenting symptom of aqueductal stenosis--case report. Neurol Med Chir (Tokyo). 2003 Dec; 43(12): 626-9.

[21] Landeiro JA, Flores MS, Lázaro BC, Melo MH. Surgical management of cerebrospinal fluid rhinorrhea under endoscopic control. ArqNeurostimulator. 2004, 62(3B): 827-31.

[22] Anand VK, Murali RK, Glasgold MJ. Surgical decisions in the management of cerebrospinal fluid rhinorrhoea. Rhinology. 1995, 33(4): 212-8.

[23] Tosun F, Gonul E, Yetiser S, Gerek M. Analysis of different surgical approaches for the treatment of cerebrospinal fluid rhinorrhea. Minim Invasive Neurosurgery. 2005, 48(6):355-60.

[24] Baban MIA, Hadi M, Gallo S, Zocchi J, Turri-Zanoni M, Castel Nuovo P. Radiological and clinical interpretation of the patients with CSF leaks developed during or after endoscopic sinus surgery. Eur Arch Otorhinolaryngol. 2017, 274(7): 2827-2835.

[25] Lee DH, Lim SC, Joo YE. Treatment outcomes of endoscopic repairs of Sino nasal cerebrospinal fluid leaks. J Craniofacial Surg. 2011 Jul;22(4):1266-70.

[26] Gata A, Trombitas VE, Albu S. Endoscopic management of frontal sinus CSF leaks. Braz J Otorhinolaryngol. 2022 Jul-Aug;88(4):576-583.

[27] Bhatti, M &Stankiewicz, James. (2003). Ophthalmic Complication of Endoscopic Sinus Surgery. Survey of ophthalmology. 48. 389-402.

[28] Çelikoğlu E, Hazneci J, Ramazanoğlu AF. Tension pneumocephalus causing brain herniation after endoscopic sinus surgery. Asian J Neurosurg. 2016 Jul-Sep;11(3): 309-10.

[29] Martínez-Capoccioni G, Serramito-García R, Cabanas-Rodríguez E, García-Allut A, Martín-Martín C. Tension pneumocephalus because of endonasal surgery: an uncommon intracranial complication. Eur Arch Otorhinolaryngol. 2014 May;271(5):1043-9. Doi: 10.1007.

[30] Kastl KG, Betz CS, Siedek V, Leunig A. Control of bleeding following functional endoscopic sinus surgery using carboxy-methylated cellulose packing. Eur Arch Otorhinolaryngol. 2009 Aug;266(8):1239-43.

[31] He Li, Yingjie Du, Wenjing Yang, Yue Wang, Shaofei Su, Xiaoyan Zhao &Guyan Wang Inhalational Anesthesia is Noninferior to Total Intravenous Anesthesia in Terms of

Surgical Field Visibility in Endoscopic Sinus Surgery: A Randomized, Double-Blind Study, Drug Design, Development and Therapy, 2023, 17, 707-716.

[32] Padhye V, Valentine R, Paramasivan S, Jardeleza C, Bassiouni A, Vreugde S, Wormald PJ. Early and late complications of endoscopic hemostatic techniques following different carotid artery injury characteristics. Int Forum Allergy Rhinol. 2014 Aug;4(8):651-7.

[33] Weidenbecher M, Huk WJ, Iro H. Internal carotid artery injury during functional endoscopic sinus surgery and its management. Eur Arch Otorhinolaryngol. 2005,262(8): 640-5.

[34] Kassam AB, Gardner PA, Snyderman CH, Carrau RL, Mintz AH, Prevedello DM. Expanded endonasal approach, a fully endoscopic transnasal approach for the resection of midline suprasellarcraniopharyngiomas: a new classification based on the infundibulum. J Neurosurg. 2008, 108(4): 715-28.

[35] Edward R. Laws. Vascular Complications of Transsphenoidal Surgery., 1999, 2(2), 163–170.

[36] Koitschev, Assen, Christian Simon, Hubert Löwenheim, Thomas Naegele and Ulrike Ernemann. "Management and outcome after internal carotid artery laceration during surgery of the paranasal sinuses." *Acta Oto-Laryngologica* 126 (2006): 730 – 738:

[37] Reich, Oleg, Kurt Ringel, Peter Stoeter and Jan Maurer. "[Injury of ICA during endonasal sinus surgery and management by endovascular stent application]." *Laryngo- rhino- otologie*: Doi: 10.1055.

[38] Weidenbecher M, Huk WJ, Iro H. Internal carotid artery injury during functional endoscopic sinus surgery and its management. Eur Arch Otorhinolaryngol. 2005, 262(8):640-5.

[39] Pepper JP, Wadhwa AK, Tsai F, Shibuya T, Wong BJ. Cavernous carotid injury during functional endoscopic sinus surgery: case presentations and guidelines for optimal management. Am J Rhinol. 2007, 21(1): 105-9.

[40] Arya, A.K., Machin, D. & Al-Jassim, H. Late periorbitalhaemorrhage following functional endoscopic sinus surgery: a caution for potential day case surgery. BMC Ear Nose Throat Disord, 6, 11 (2006).

[41] EL Desouky, Mohamed. (2021). Evaluation & management of orbital hemorrhage. 10.13140.

[42] Kim, Hyun & Kim, Chang-Hoon& Song, Min & Yoon, Joo-Heon. Diplopia secondary to endoscopic sinus surgery. Actaotolaryngologic. 2005, 124. 1237-9.

[43] Sohn, J.H. & Hong, S.D. & Kim, J.H. &Dhong, H.-J & Chung, Seung-Kyu& Kim, Hyo& Oh, S.Y. Extraocular muscle injury during endoscopic sinus surgery: a series of 10 cases at a single center. Rhinology journal. 2014, 52. 238-245.

[44] Ingrid Raponi, Filippo Giovannetti, Matteo Buracchi, Paolo Priore, Andrea Battisti, MirkoScagnet, Lorenzo Genitori, Valentino Valentini, Management of orbital and brain complications of sinusitis: A practical algorithm, Journal of Cranio-Maxillofacial Surgery, 2021, 49(12): 1124-1129.

[45] Mehta, A., Rathod, R., Arora, K. *et al*. Endoscope Assisted Combined Drainage of Sino-Orbital Abscess: Technique Revisited. *Indian J Otolaryngol Head Neck Surg*, 2022, 74, 172–177.

[46] Bhargava D, Sankhla D, Ganesan A, Chand P. Endoscopic sinus surgery for orbital subperiosteal abscess secondary to sinusitis. Rhinology. 2001, 39(3): 151-5.

[47] Brook I, Friedman EM, Rodriguez WJ, Controni G. Complications of sinusitis in children. Pediatrics. 1980, 66(4): 568-72.

[48] Dolan RW, Chowdhury K. Diagnosis, and treatment of intracranial complications of paranasal sinus infections. J Oral Maxillofacial Surg. 1995 Sep, 53(9):1080-7.

[49] Harris, Gerald J, Subperiosteal Abscess of the Orbit. Ophthalmology, 1994, 101(3), 585–595.

[50] Younis RT, Anand VK, Childress C. Sinusitis complicated by meningitis: current management. Laryngoscope. 2001, 111(8): 1338-42.

[51] Radovani P, Vasili D, Xhelili M, Dervishi J. Orbital complications of sinusitis. Balkan Med J. 2013 Jun; 30(2): 151-4.

[52] Sansa-Perna A, Gras-Cabrerizo JR, Montserrat-Gili JR, Rodríguez-Álvarez F, Massegur-Solench H, Casasayas-Plass M. Our experience in the management of orbital complications in acute rhinosinusitis. Acta Otorhinolaryngology Esp (Engl Ed). 2020 Sep-Oct, 71(5): 296-302.

[53] Pal, D & Bhattacharyya, Avik& Husain, M. Omair& Prasad, Kashi&Pandey, Chandra & Gupta, R.K... (2009). In Vivo Proton MR Spectroscopy Evaluation of Pyogenic Brain Abscesses: A Report of 194 Cases. AJNR. American journal of neuroradiology. 2009, 31. 360-6.

[54] Fenton JE, Smyth DA, Viani LG, Walsh MA. Sinogenic brain abscess. Am J Rhinol. 1999 Jul-Aug;13(4):299-302.

[55] May M, Levine HL, Mester SJ, Schaitkin B. Complications of endoscopic sinus surgery: analysis of 2108 patients--incidence and prevention. Laryngoscope.1994, 104(9): 1080-3.

[56] McInnes G, Howes DW. Lateral canthotomy and cantholysis: a simple, vision-saving procedure. CJEM. 2002 Jan; 4(1): 49-52.

[57] Bhatti MT, Schmalfuss IM, Mancuso AA. Orbital complications of functional endoscopic sinus surgery: MR and CT findings. Clin Radiol. 2005 Aug; 60(8): 894-904.

[58] Suzuki H, Inaba T, Hiraki N, Hashida K, Wakasugi T, Kadokawa Y, Udaka T. Endoscopic sinus surgery for the treatment of organized hematoma of the maxillary sinus. Kurume Med J. 2008, 55(3-4): 37-41.

[59] Laxmi, S., Tunkel, A.R. Healthcare-Associated Bacterial Meningitis. *Curr Infect Dis Rep*, 2011, 13, 367–373.

[60] VirginieZarrouk, Isabelle Vassor, Frederic Bert, Didier Bouccara, Michel Kalamarides, Noelle Bendersky, Aimée Redondo, Olivier Sterkers, Bruno Fantin, Evaluation of the Management of Postoperative Aseptic Meningitis, *Clinical Infectious Diseases*, 2007, 44(12): 1555–1559.

[61] Tunkel, Allan R., Barry J. Hartman, Sheldon L. Kaplan, Bruce A. Kaufman, Karen L. Roos, W. Michael Scheld, and Richard J. Whitley. "Practice guidelines for the management of bacterial meningitis." *Clinical infectious diseases*, 39, 9 (2004): 1267-1284.

[62] Al-Afif S, Hermann EJ, Hatipoglu Majernik G, Nakamura M, Raab P, Lenarz T, Krauss JK. Severe Cerebral Complications Secondary to Perforation Injury of the Anterior Skull Base During Sinonasal Surgery: An Underappreciated Problem World Neurosurg. 2017 Dec; 108: 783-790.

[63] Taasan V, Wynne JW, Cassisi N, Block AJ. The effect of nasal packing on sleep-disordered breathing and nocturnal oxygen desaturation. Laryngoscope 1981; 91(7): 1163–72.

[64] Serdahl CL, Berris CE, Chole RA. Nasolacrimal duct obstruction after endoscopic sinus surgery. Arch Ophthalmology. 1990 Mar;108(3):391-2.

[65] Tatlisumak, Ertugrul & Aslan, Asım & Comert, Ayhan & Ozlugedik, Samet & Acar, Halil& Tekdemir, Ibrahim. (2009). Surgical anatomy of the nasolacrimal duct on the lateral nasal wall as revealed by serial dissections. Anatomical science international, 2009, 85. 8-12.

[66] Unlu HH, Goktan C, Aslan A, Tarhan S. Injury to the lacrimal apparatus after endoscopic sinus surgery: surgical implications from active transport dacryocystography. Otolaryngol Head Neck Surg. 2001 Mar;124(3):308-12.